Linus Health

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that specializes in brain health monitoring through innovative technology. The company has developed a multi-modal analytics platform that utilizes artificial intelligence, signal processing, and speech analytics to detect subtle changes in neurological health. By converting smartphones and tablets into effective brain health monitors, Aural Analytics enables the collection of objective and interpretable data. This technology supplements traditional functional rating scales used in clinical trials, providing continuous and reliable metrics for assessing the effectiveness of medical interventions. Aural Analytics' platform captures clinically relevant speech, fine motor, and linguistic samples to offer healthcare professionals accurate assessments of patient health, thereby enhancing the understanding of disease progression.

Kinesis Health Technologies is a Dublin-based digital health company founded in 2013, specializing in solutions for assessing physical function and preventing falls risk in older adults. The company has developed a patented platform that monitors and identifies mobility impairments by categorizing various mobility parameters, including walking, variability, symmetry, transfers, and turning. By comparing patients' mobility scores against population data based on age and gender, Kinesis Health Technologies provides a comprehensive method for evaluating falls risk and assessing gait, mobility, and frailty in a standardized manner. The team behind Kinesis Health Technologies possesses extensive experience in business, marketing, and technology, supported by 12 years of research conducted in Ireland.

Digital Cognition Technologies, Inc. specializes in the research and development of non-invasive tests designed to detect presymptomatic cognitive impairment. The company’s innovative approach involves analyzing micro-movements in drawing behavior, which provide insights into an individual's memory and thinking processes. These tests are utilized in various contexts, including drug development, where they facilitate the pre-screening of participants and help assess the efficacy of treatments by identifying subtle cognitive changes. Additionally, the tests support researchers in early detection and intervention strategies, enabling timely treatment with both investigational therapies and established medications. Founded in 2015 and based in Waltham, Massachusetts, Digital Cognition Technologies aims to enhance patient care and improve treatment outcomes through early identification of cognitive decline.